Emerging EZH2 Inhibitors and Their Application in Lymphoma

@article{Lue2018EmergingEI,
  title={Emerging EZH2 Inhibitors and Their Application in Lymphoma},
  author={J. Lue and Jennifer E Amengual},
  journal={Current Hematologic Malignancy Reports},
  year={2018},
  volume={13},
  pages={369-382}
}
  • J. Lue, Jennifer E Amengual
  • Published 2018
  • Medicine
  • Current Hematologic Malignancy Reports
    • Purpose of ReviewEnhancer of Zeste Homolog 2 (EZH2) is histone methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of transcriptional repression. Various studies have elucidated the complex role of EZH2 in both normal biology and tumorigenesis. Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma.Recent FindingsActivating mutations and overexpression of EZH2 are… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    29 Citations
    Highly Influential Citations
    1
    Background Citations
    13
    29 Citations
    Citation Type

    Citation Type

    EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
    • 12
    EZH2-Targeted Therapies in Cancer: Hype or a Reality
    • 4
    Hypomethylating Agents in Lymphoma
    BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer
    • 13
    Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b
    • PDF
    EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
    • 4
    • PDF
    Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Development of molecular intervention strategies for B-cell lymphoma
    EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma
    • PDF
    β-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer.
    • 4

    References

    SHOWING 1-10 OF 124 REFERENCES
    Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
    • 119
    EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
    • 1,297
    Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas
    • 3
    Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
    • Wei Qi, H. Chan, +25 authors E. Li
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences
    • 2012
    • 457
    • PDF
    EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models
    • 5
    • PDF
    Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
    • 149
    • PDF
    Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
    • 332
    • PDF
    A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    • 602
    • PDF
    EZH2: Not EZHY (Easy) to Deal
    • 82
    • PDF
    First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results
    • 19